GLP-1’s “aftermath” is boosting breast implant demand—why Establishment Labs could be the next device-spillover trade

In a Sept. 2, 2026 call highlighted by CNBC, TD Securities flagged Establishment Labs as a beneficiary of widening GLP-1 adoption—specifically through increased U.S. breast augmentation procedures tied to post-weight-loss body changes. The note’s core claim is that GLP-1’s popularity is fueling aesthetic surgery volumes, with TD pointing to measurable procedure-growth figures in the U.S. and a thesis that this can expand Establishment Labs’s addressable implant market as its U.S. portfolio scales.

For Establishment Labs, that last step matters. The company’s public filings describe substantially all revenue as coming from silicone gel-filled breast implants under the Motiva Implants brand, with U.S. commercialization timelines explicitly tied to approvals and sales start dates.

CNBC’s Sept. 2 write-up (describing TD Securities’ note) cites several figures used to connect GLP-1 adoption to aesthetic procedure demand: roughly one in eight adults reporting GLP-1 use in 2025; U.S. cosmetic surgery market growth reaching 7% in 2025; and U.S. breast augmentation volumes up 11%, with breast lifts up 8%. The note then emphasizes that GLP-1-driven weight loss is fueling increased demand and that it accelerated certain breast-augmentation demand by 10% in the U.S., alongside “more than 20%” growth in multiple post-weight-loss categories.

The key investor question is not whether the procedure story is catchy—it is whether increased procedure demand is converting into durable revenue growth and (eventually) operating leverage. On the financials available for Establishment Labs, the company has generated revenue growth from FY2023 to FY2025, but remains loss-making on both operating income and free cash flow in the latest periods shown.

In its FY2025 10-K (filed Feb. 27, 2026), Establishment Labs states: Motiva Implants U.S. approval was received in September 2024; the company began selling Motiva Implants for breast augmentation in the U.S. in October 2024; and Motiva Flora Tissue Expander approval was October 2023. It also discloses revenue concentration: the U.S. accounted for 21.6% of consolidated revenue in 2025, and no other single country exceeded 10%.

Short-term (days to quarters): validate whether sell-side targets and market expectations for Establishment Labs are accompanied by any actual indicators of U.S. demand conversion—guided by management updates, sales momentum, and whether loss-making continues or stabilizes. Long-term (1–3 years): track whether the Motiva U.S. launch effects show up as sustained revenue growth and improved operating leverage, which would support that GLP-1’s second-order effect is structurally expanding device demand rather than temporarily lifting discretionary procedure schedules.